Adaptive Biotechnologies Management
Management criteria checks 2/4
Adaptive Biotechnologies' CEO is Chad Robins, appointed in Sep 2009, has a tenure of 15.33 years. total yearly compensation is $8.90M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth $13.07M. The average tenure of the management team and the board of directors is 6.3 years and 9 years respectively.
Key information
Chad Robins
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 7.4% |
| CEO tenure | 15.3yrs |
| CEO ownership | 1.2% |
| Management average tenure | 6.3yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Adaptive Biotechnologies: Making Some Progress
Nov 26Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Nov 26
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
Compensation vs Market: Chad's total compensation ($USD8.90M) is above average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.
CEO
Chad Robins (50 yo)
15.3yrs
Tenure
US$8,904,267
Compensation
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | US$8.90m | 1.23% $ 13.1m | |
| President & COO | 6.9yrs | US$2.97m | 0.32% $ 3.4m | |
| Co-Founder & Chief Scientific Officer | 15.3yrs | US$8.61m | 0.69% $ 7.4m | |
| Chief Commercial Officer of Immune Medicine | 6.9yrs | US$2.88m | 0.22% $ 2.4m | |
| Founder | no data | no data | no data | |
| VP, CFO & Principal Accounting Officer | 3.3yrs | US$1.66m | 0.10% $ 1.1m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief People Officer | 5.8yrs | no data | 0.17% $ 1.8m | |
| Chief Commercial Officer of MRD | 4.4yrs | no data | 0.17% $ 1.8m | |
| Senior Vice President of MRD BioPharma | 1.3yrs | no data | no data |
6.3yrs
Average Tenure
50yo
Average Age
Experienced Management: ADPT's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | US$8.90m | 1.23% $ 13.1m | |
| Lead Independent Director | 11.1yrs | US$355.00k | 0.093% $ 993.4k | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Independent Director | 5.8yrs | US$330.00k | 0.035% $ 374.0k | |
| Independent Director | 11.9yrs | US$325.00k | 0.051% $ 547.0k | |
| Independent Director | 6.9yrs | US$310.00k | 0.037% $ 390.9k | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Independent Director | 3.8yrs | US$310.00k | 0.038% $ 404.1k |
9.0yrs
Average Tenure
58.5yo
Average Age
Experienced Board: ADPT's board of directors are considered experienced (9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 08:33 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adaptive Biotechnologies Corporation is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Daniel Leonard | Credit Suisse |